Synlett 2006(5): 0725-0728  
DOI: 10.1055/s-2006-933130
LETTER
© Georg Thieme Verlag Stuttgart · New York

A Facile Synthesis of 1-Substituted Cyclopropylsulfonamides

Jianqing Li*, Daniel Smith, Henry S. Wong, Jeffrey A. Campbell, Nicholas A. Meanwell, Paul M. Scola
Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
Fax: +1(203)6777702; e-Mail: Jianqing.Li@bms.com;
Further Information

Publication History

Received 28 November 2005
Publication Date:
09 March 2006 (online)

Abstract

A practical, convenient, and high-yielding three-step synthesis of cyclopropanesulfonamide and 1-substituted cyclopropanesulfonamides, starting from 3-chloropropanesulfonyl chloride, is described.

    References and Notes

  • A Scifinder search based on substructure A revealed more than 90 patents claiming bioactivities of cyclosulfonamide derivatives. See:
  • 1a Greenlee WJ, Huang Y, Kelly JM, McCombie SW, Stamford AW, and Wu Y. inventors; US Patent Appl.  2003/114517. 
  • 1b Miller MW, and Scott JD. inventors; PCT Int. Appl. WO  2004/056770. 
  • 1c Paliwal S, Reichard GA, Wang C, Xiao D, Tsui H.-C, Shih N.-Y, Arredondo JD, Wrobleski ML, and Palani A. inventors; PCT Int. Appl. WO  2003/051840. 
  • 1d De Nanteuil G, Portevin B, Benoist A, Levens N, Nosjean O, and Husson-Robert B. inventors; Eur. Pat. Appl.  1245568. 
  • 1e Llinas-Brunet M, and Bailey MD. inventors; PCT Int. Appl. WO  2004/037855. 
  • 1f Glunz PW, Bisacchi GS, Morton GC, Holubec AA, Priestley ES, Zhang X, and Treuner UD. inventors; PCT Int. Appl. WO  2004/072101. 
  • 1g Walter R, Heckel A, Roth GJ, Kley J, Schnapp G, Lenter M, Van Meel JCA, Spevak W, and Weyer-Czernilofsky U. inventors; PCT Int. Appl. WO  2002/36564. 
  • 1h Zhu HY, Njoroge FG, Cooper AB, Guzi T, Dinanath FR, Minor KP, Doll RJ, Girijavallabhan VM, Santhanam B, Pinto PA, Vibulbhan B, Keertikar KM,
    Alvarez
    CS, Baldwin JJ, Li G, Huang C.-Y, James RA, Bishop WR, Wang JJ.-S, and Desai JA. inventors; US Patent Appl.  2004/122018. 
  • 1i Allen DG, Coe DM, Cook CM, Cooper AWJ, Dowle MD, Edlin CD, Hamblin JN, Johnson MR, Jones PS, Lindvall MK, Mitchell CJ, and Redgrave AJ. inventors; PCT Int. Appl. WO  2004/056823. 
  • 1j Breitfelder S, Cirillo PF, and Regan JR. inventors; PCT Int. Appl. WO  2002/083642. 
  • 1k Brendel J, Pirard B, Peukert S, Kleemann H.-W, and Hemmerle H. inventors; PCT Int. Appl. WO  2002/088073. 
  • 2a Truce WE. Goralski CT. J. Org. Chem.  1968,  33:  3849 
  • 2b Brienne M.-J. Varech D. Leclercq M. Jacques J. Radembino N. Dessalles M.-C. Mahuzier G. Gueyouche C. Bories C. Loiseau P. Gayral P. J. Med. Chem.  1987,  30:  2232 
  • 3a Christensen LW. Seaman JM. Truce WE. J. Org. Chem.  1973,  38:  2243 
  • 3b Makosza M. Golinski J. Ostrowski S. Rykowski A. Sahasrabudhe AB. Chem. Ber.  1991,  124:  577 
  • 4a Kosinski S. Wojciechowski K. Eur. J. Org. Chem.  2000,  1263 
  • 4b Meyle E. Schwenkkraus P. Zsigmondy M. Otto H.-H. Arch. Pharm.  1989,  322:  17 
  • 5a Truce WE. Goralski CT. J. Org. Chem.  1969,  34:  3324 
  • 5b Neale RS. Marcus NL. J. Org. Chem.  1969,  34:  1808 
  • 6a Block E. Schwan A. Dixon DA. J. Am. Chem. Soc.  1992,  114:  3492 
  • 6b King JF. Lam JYL. Ferrazzi G. J. Org. Chem.  1993,  58:  1128 
  • 7 Thompson ME. J. Org. Chem.  1984,  49:  1700 
  • 8 Neustadt BR. Tetrahedron Lett.  1994,  35:  379 
  • 9 Campbell JA. Hart DJ. J. Org. Chem.  1993,  58:  2900 
  • 10a Rawal VH. Cava MP. Tetrahedron Lett.  1985,  26:  6141 
  • 10b Reuter DC. McIntosh JE. Guinn AC. Madera AM. Synthesis  2003,  2321 
  • 11 White EH. Lim HM. J. Org. Chem.  1987,  52:  2162 
  • 14 Campbell JA, D’Andrea S, Good A, Li J, McPhee F, Ripka A, Scola PM, and Tu Y. inventors; US Patent Appl.  2004/0077551. For procedures on synthesis of 3a,c, 4b, 5b and removal of t-Boc group, see:
12

Procedure for the Synthesis of 8.
tert-Butylamine (2a, 3.0 mol, 315.3 mL) was dissolved in THF (2.5 L). The solution was cooled to -20 °C and
3-chloropropanesulfonyl chloride (1, 1.5 mol, 182.4 mL) was added slowly. The reaction mixture was allowed to warm to r.t. and stirred for 24 h. The mixture was filtered, and the filtrate concentrated in vacuo. The residue was dissolved in CH2Cl2 (2.0 L), washed with 1 N HCl (1.0 L), H2O (1.0 L) and brine (1.0 L) before being dried over Na2SO4. The solution was filtered and concentrated in vacuo to give a slightly yellow solid, which was crystallized from hexane to afford the product 3b as a white solid (316.0 g, 99%). Mp 70-72 °C. 1H NMR (500 MHz, CDCl3): δ = 1.37 (s, 9 H, 3 × CH3), 2.25-2.30 (m, 2 H, CH2), 3.21 (t, J = 7.5 Hz, 2 H, CH2), 3.67 (t, J = 7.5 Hz, 2 H, CH2), 4.36 (br s, 1 H, NH). 13C NMR (125 MHz, CDCl3): δ = 27.4, 30.4, 42.9, 53.4, 54.9. Anal. Calcd for C7H16NO2S: C, 39.33; H, 7.54; N, 6.55. Found: C, 39.37; H, 7.33; N, 6.49.
To a stirred solution of compound 3b (0.75 mol, 160 g) in dry THF (2 L) at -78 °C under N2 was added slowly a solution of n-BuLi (2.5 M in hexane, 2.1 equiv, 1.575 mol, 630 mL). After addition, the dry ice bath was removed and the reaction mixture was allowed to warm to r.t. over a period of 2 h. The reaction mixture was cooled to 0 °C and quenched with sat. NH4Cl solution (500 mL). The THF was removed in vacuo and the residue partitioned between EtOAc (1.5 L) and H2O (1 L). The organic phase was separated, washed with brine (1 L) and dried over MgSO4 before being filtered and concentrated in vacuo to give a white solid which was recrystallized from hexane to give the product 7a as white needles (125.0 g, 94%). Mp 81-83 °C. 1H NMR (500 MHz, CDCl3): δ = 0.96-1.00 (m, 2 H, CH2), 1.16-1.19 (m, 2 H, CH2), 1.38 (s, 9 H, 3 × CH3), 2.43-2.47 (m, CH), 4.23 (br s, 1 H, NH). 13C NMR (125 MHz, CDCl3): δ = 6.5, 30.7, 33.6, 54.3. Anal. Calcd for C7H15NO2S: C, 47.43; H, 8.52; N, 7.90. Found: C, 47.53; H, 8.49; N, 7.74.
A solution of compound 7a (0.62 mol, 110.0 g) in TFA (500 mL) was stirred at r.t. under N2 for 16 h. The TFA was removed in vacuo to give a yellow oil which was crystallized from EtOAc-hexane (1:3, 300 mL) to afford product 8 as white needles (68.5 g, 91%). Mp 106-107 °C. 1H NMR (500 MHz, DMSO): δ = 0.87-0.93 (m, 4 H, 2 × CH2), 2.49-2.54 (m, 1 H, CH), 6.76 (br s, 2 H, NH2). 13C NMR (125 MHz, DMSO): δ = 4.90, 32.0. Anal. Calcd for C3H7NO2S: C, 29.74; H, 5.82; N, 11.56. Found: C, 30.02; H, 5.61; N, 11.37.

13

Typical Procedure Exemplified by the Preparation of 1-Methylcyclopropylsulfonamide (Table, Entry 1).
To a solution of 3b (20 mmol, 4.3 g) in dry THF (100 mL) under N2 was added a solution of n-BuLi (2.5 M in hexane, 2.1 equiv, 44 mmol, 17.6 mL) at -78 °C. The reaction mixture was allowed to warm to r.t. over a period of 1.5 h and then was cooled to -78 °C. Another equivalent of
n-BuLi (8 mL) was added, the mixture warmed to r.t. over a period of 1.5 h and then recooled to -78 °C. The MeI (2 equiv, 40 mmol, 2.5 mL) was added and the reaction mixture was allowed to warm to r.t. over a period of 12 h. The mixture was quenched with a solution of sat. NH4Cl (100 mL) and extracted with EtOAc (100 mL). The organic extract was washed with brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to give a yellow oil which was crystallized from hexane to afford the product as slightly yellow needles (3.1 g, 81%). Mp 77-78 °C. 1H NMR (500 MHz, CDCl3): δ = 0.77-0.80 (m, 2 H, CH2), 1.38-1.41 (m, 2 H, CH2), 1.36 (s, 9 H, 3 × CH3), 1.51 (s, 3 H, CH3), 4.07 (br s, 1 H, NH). 13C NMR (125 MHz, CDCl3): δ = 13.8, 19.0, 30.9, 37.3, 54.4. Anal. Calcd for C8H17NO2S: C, 50.23; H, 8.95; N, 7.32. Found: C, 50.05; H, 8.80; N, 7.32.
Treatment of this material (10 mmol, 1.91 g) with TFA (30 mL) using the same procedure described above for 8 gave the product as a white solid (1.25 g, 96%). Mp 103-104 °C. 1H NMR (500 MHz, DMSO): δ = 0.74 (dd, J = 6.1, 4.0, 2 H, CH2), 1.13 (dd, J = 6.1, 4.0, 2 H, CH2), 1.44 (s, 3 H, CH3), 6.72 (br s, 2 H, NH2). 13C NMR (125 MHz, DMSO): δ = 12.1, 17.6, 36.4. Anal. Calcd for C4H9NO2S: C, 35.54; H, 6.71; N, 10.36. Found: C, 35.67; H, 6.80; N, 10.40.